Several studies indicate that women with breast cancer who undergo radiotherapy are susceptible to secondary lung cancer, whether they are smokers or nonsmokers. However, all studies to date have methodological limitations and have been small. Also, none have used molecular markers, which can improve exposure assessments or elucidate mediating mechanisms. Over time, radiotherapy methods have changed and doses to the lung have lessened. On the other hand, prevalence of smoking has increased among women in the western world. The identification of lung cancer risk is important in the context of the debates for benefits of radiation therapy in good prognosis tumors or older women. Thus, a study of breast and secondary lung cancer is needed to improve dosimetry assessments for radiation induced lung cancer, with and without an interactive effect of smoking. Also, studying a unique population of women who have had both breast and lung cancer can provide new insights into carcinogeneis and cancer risk. In order to do this, we are proposing a population-based study using the Swedish Cancer Registry (SCR) and determination of radiation doses to the whole lung and side of the lung where the tumor subsequently develops. Reliable smoking data will be available.
Our specific aims are to: 1) determine risk factors for secondary lung cancer in women treated with radiotherapy for breast cancer using complementary nested case-control and case-only study designs (n=559 cases and 559 matched controls); 2) to determine p53 inactivation pathways, (i.e., mutational spectra and loss of heterozygosity) in lung tumors of women with a prior history of breast cancer (n=402) and; 3) to determine the frequency of p53 inactivation pathways in breast tumors of women who did and did not develop lung cancer, and compare them to the frequency of p53 inactivation pathways in the lung tumors (n=342 cases and 342 controls).
The first aim will allow us to identify risks.
The second aim will provide information about the mechanistic relationship of radiotherapy to lung cancer and may identify a unique spectrum for radiation-related lung cancer.
The third aim considers the combined occurrence of breast and lung cancer in a woman as phenotype of susceptibility for multiple primary cases. This study provides unique opportunities. Using the SCR and the unparalleled ability to obtain tissue blocks dating back to the 1950's, we can provide new data to understand risk in the context of molecular markers, especially because we will be able to retrieve the tumor blocks from both the breast and lung cancer from the same women. ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA092705-01A2
Application #
6573220
Study Section
Special Emphasis Panel (ZRG1-SNEM-5 (02))
Program Officer
Starks, Vaurice
Project Start
2003-01-15
Project End
2007-12-31
Budget Start
2003-01-15
Budget End
2003-12-31
Support Year
1
Fiscal Year
2003
Total Cost
$593,059
Indirect Cost
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Luta, George; Ford, Melissa B; Bondy, Melissa et al. (2013) Bayesian sensitivity analysis methods to evaluate bias due to misclassification and missing data using informative priors and external validation data. Cancer Epidemiol 37:121-6
Marian, Catalin; Ochs-Balcom, Heather M; Nie, Jing et al. (2011) FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. Int J Cancer 129:702-12
Tennis, M; Singh, B; Hjerpe, A et al. (2010) Pathological confirmation of primary lung cancer following breast cancer. Lung Cancer 69:40-5
Yogev-Seligmann, Galit; Rotem-Galili, Yael; Mirelman, Anat et al. (2010) How does explicit prioritization alter walking during dual-task performance? Effects of age and sex on gait speed and variability. Phys Ther 90:177-86
Tennis, Meredith; Krishnan, Shiva; Bonner, Matthew et al. (2006) p53 Mutation analysis in breast tumors by a DNA microarray method. Cancer Epidemiol Biomarkers Prev 15:80-5